Pharmaceutical companies treat time as their most expensive commodity. In an industry where a patent clock starts ticking long before […]

The pharmaceutical industry, by its very nature, is a landscape defined by cycles of innovation and competition. For decades, the

The Boundary Between Pharmacy Practice and Unapproved Manufacturing The pharmaceutical industry currently stands at a critical inflection point where the

The pharmaceutical industry operates on a paradox. A company spends a decade and $2.6 billion to invent a single molecule,

Why Traditional Valuation Fails in the Life Sciences Valuation in the life sciences deviates fundamentally from the rules governing software

The Disconnect Between Science and Spreadsheet Valuing a biotechnology or pharmaceutical company differs from evaluating a standard cash-flow-positive business. In

The geographic distribution of pharmaceutical patent litigation in the United States is currently undergoing its most significant realignment since the

Executive Strategic Analysis The pharmaceutical sector currently faces a structural conflict between two divergent regulatory and legal regimes: the intellectual

The End of the Binary Patent System The pharmaceutical industry has historically operated under a binary commercial model: a drug